HealthLynked Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Rosal David, was filed 24 Jun 2024.
HealthLynked Corp: what insiders have been doing
This page follows insider dealings at HealthLynked Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Nothing new has been filed by managers of HealthLynked Corp in twelve months, the latest record being from 24 June 2024.
Looking back to 2019, when coverage begins, insiders filed 5 purchases and no sales. The 10-K for the year ended 31 December 2025 shows 2.1 m USD of revenue and -3.3 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -76.3%Entry US$8.00 · Close at T+365 US$1.90
- -75.7%Entry US$99.00 · Close at T+365 US$24.10
- -75.7%Entry US$99.00 · Close at T+365 US$24.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 28,333 shares@ US$0.08446.9% of flowCommon stockSEC:0001213900-24-055207:1Canonical exit: 22 Sept 2024 (T+90)
- 33,667 shares@ US$0.08100.0% of flowCommon stockSEC:0001213900-24-055207:0Canonical exit: 18 Sept 2024 (T+90)
- 408,163 shares0Common StockSEC:0001013762-23-002528:0
- 408,163 shares0Common StockSEC:0001013762-23-002527:0
- 408,163 shares0Common StockSEC:0001013762-23-002530:0
- 408,163 shares0Common StockSEC:0001013762-23-002529:0
- 50,000 shares0Common stockSEC:0001213900-23-006421:0
- 50,000 shares0Common stockSEC:0001213900-23-006422:0
- 536,193 shares0Common StockSEC:0001213900-22-079100:0
- 536,193 shares0Common StockSEC:0001213900-22-079102:0
- 536,193 shares0Common StockSEC:0001213900-22-079099:0
- 400,000 shares0Common stockSEC:0001213900-22-065570:0
- 2,000 shares0Common stockSEC:0001213900-22-003088:0
- 2,000 shares0Common stockSEC:0001213900-22-003090:0
- 74,766 shares0Common StockSEC:0001213900-21-061949:0
- 74,766 shares0Common StockSEC:0001213900-21-061950:0
- 74,766 shares0Common StockSEC:0001213900-21-061952:0
- 74,766 shares0Common StockSEC:0001213900-21-061947:0
- 68,942 shares0Common StockSEC:0001213900-21-060016:0
- 68,942 shares0Common StockSEC:0001213900-21-060015:0
- 68,942 shares0Common StockSEC:0001213900-21-060058:0
- 68,942 shares0Common StockSEC:0001213900-21-060022:0
- 312,250 shares@ US$0.10100.0% of flowCommon StockSEC:0001213900-21-049362:0
- 81,288 shares0Common StockSEC:0001213900-21-024487:0
- 289,694 shares0Common StockSEC:0001213900-21-024484:0
25 of 39 declarations
About HealthLynked Corp
HealthLynked Corp. (ticker: HLYK) is a U.S.-listed healthcare technology and services company. As of the latest filings reviewed, its common stock was quoted on the OTCQB, while the company had filed to list on the Nasdaq Capital Market, with a target transition in 2026. HealthLynked is based in Naples, Florida, and is incorporated in Nevada. For investors in France, Belgium, and Switzerland, the company is best understood as a small-cap healthcare platform with a hybrid model combining digital health software and direct clinical operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1680139/000121390026013824/ea0275639-s1_health.htm))
HealthLynked was built around the vision of Dr. Michael Dent, a physician-entrepreneur associated with the founding of NeoGenomics. The company was incorporated in 2014 and developed from an initial healthcare-network concept into a broader platform designed to improve the exchange of medical information between patients and providers. Its stated mission is to make healthcare more efficient by enabling accurate data transfer, better practice workflows, improved access to care, and more coordinated clinical decision-making. ([healthlynked.com](https://www.healthlynked.com/about-us/?utm_source=openai))
Read moreShow less
The business is structured around two core divisions. The Digital Healthcare division is centered on the HealthLynked Network, a cloud-based platform for medical record management, appointment scheduling, telemedicine, and concierge-style healthcare coordination. The Health Services division includes operating medical practices in Florida, including Naples Center for Functional Medicine, Concierge Care Naples, and Aesthetic Enhancements Unlimited; the company also sold its Bridging the Gap Physical Therapy practice in October 2025. This structure gives HealthLynked a rare combination of software-enabled patient engagement and real-world clinical delivery. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1680139/000121390025026262/R8.htm))
From a competitive standpoint, HealthLynked is still a development-stage or emerging growth story rather than a scaled healthcare platform. Its investment case rests on whether it can convert its network, software features, and local practice footprint into recurring revenue and broader adoption. The company continues to position the HealthLynked Network as a tool that can improve patient-provider connectivity, while also supporting ancillary revenue streams such as medical product distribution through MedOfficeDirect. ([investors.healthlynked.com](https://investors.healthlynked.com/presstype/healthlynked-completes-acquisition-of-medofficedirect-llc-adding-discounted-medical-supplies-for-patient-members-and-healthcare-providers/?utm_source=openai))
Recent developments are important. In February 2025, HealthLynked highlighted the launch of ARI, its AI-powered healthcare guidance feature, alongside broader product enhancements aimed at improving patient engagement. In November 2025, the company announced an advisory engagement to support a Nasdaq listing roadmap, and its February 2026 prospectus still described the stock as OTCQB-quoted while stating that Nasdaq Capital Market listing preparations were underway. These announcements indicate that management is pursuing both product expansion and capital-markets repositioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1680139/000121390025009700/ea022973501ex99-2_health.htm))
